Close
To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the听hyperlinked听Local Project Reference (LRP)听ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Lung cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
听
APL-101-01Safety and efficacy of APL-101 in NSCLC and advanced solid tumors:听 Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | |
|---|---|
| Local Project Reference: | |
| Principal Investigator: | Dr. Martin Forster |
| Drug Class/ Treatment: | APL-101听(C-Met Inhibitor) |
| Patient Population: | Non-Small Cell Lung Cancer (NSCLC) |
| Trial Hosted By - UCLH Clinical Research Facility (CRF) | |
FURMO 002A PHASE 1b DOSE ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF FURMONERTINIB IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH ACTIVATING EGFR OR HER2 MUTATIONS, INCLUDING EXON 20 INSERTION MUTATIONS | |
|---|---|
| Local Project Reference: | |
| Principal Investigator: | Dr Martin Forster |
| Drug Class/Treatment: | Furmonertinib听(EGFR Tyrosine-Kinase Inhibitor) |
| Patient Population: | Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutations听(Including Exon 20 Insertion Mutations) |
| Trial Hosted By - UCLH Clinical Research Facility (CRF) | |
KisMET-01 (MYTX-011-01)A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-DrugConjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer - KisMET-01 | |
|---|---|
| Local Project Reference: | |
| Principal Investigator: | Dr Sarah Benafif |
| Drug Class/Treatment: | MYTX-011听(cMET-Targeted Valine-Citrulline Monomethyl Auristain E (vcMMAE) ADC) |
| Patient Population: | Non-Small Cell Lung Cancer (NSCLC) |
| Trial Hosted By - UCLH Clinical Research Facility (CRF) | |
CCR4220: HyPeRHyper: A Phase 1, Dose Escalation Study Of SGI-110, A Second-Generation Hypo-Methylating Agent In Combination With Pembrolizumab (MK3475) In Patients With Refractory Solid Tumors | |
|---|---|
| Local Project Reference: | 听 |
| Principal Investigator: | Dionysis Papadatos-Pastos |
| Drug Class/Treatment: | ASTX727 (Fixed-dose combination of Decitabine and Cedazuridine) + Pembrolizumab |
| Patient Population: | Refractory Solid Tumours:
|
| Trial Hosted By - UCLH Clinical Research Facility (CRF) | |
听
ATX-NS-001 (CHIRON)ATX-NS-001 - ATL001 for the Treatment of Non-Small Cell Lung Cancer: 听An open label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neo-antigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON) | |
|---|---|
| Local Project Reference: | |
| Principal Investigator: | Dr. Martin Forster |
| Drug Class/ Treatment: | ATL001 -听Autologous Clonal Neoantigen Reactive T-Cell (cNeT) |
| Patient Population: | Non-Small Cell Lung Cancer (NSCLC) |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
PALOMA-2A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer | |
|---|---|
| Local Project Reference: | |
| Principal Investigator: | Dr Sarah Benafif |
| Drug Class/ Treatment: | Amivantamab (Bi-specific EGF & MET Receptor-Directed Antibody) Subcutaneous |
| Patient Population: | Non-Small Cell Lung Cancer (NSCLC):
|
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
CONCORDEA platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer | |
|---|---|
| Local Project Reference: | |
| Principal Investigator: | Dr. Crispin Hiley |
| Drug Class/ Treatment: | Radiotherapy + Olaparib (PARP Inhibitor)听or AZD1390 (Oral ATM Inhibitor) |
| Patient Population: | Non-Small Cell Lung Cancer |
| Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) | |
听
听
听
听
| LuCa-MERIT-1 (BNT116-01) LuCa-MERIT-1: First-in-human, open label, Phase I dose confirmation trial evaluating the safety, tolerability and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer | |
|---|---|
| Local Project Reference: | 161258 |
| Principal Investigator: | Dr Sarah Benafif |
| Drug Class/Treatment: | BNT116听(mRNA Vaccine) Monotherapy and Combination with Immunotherapies |
| Patient Population: | Non-Small Cell Lung Cancer (NSCLC) |
| Trial Hosted By - UCLH Clinical Research Facility (CRF) | |
听
